Regeneron Pharmaceuticals
Market Cap
US$53.7b
Last Updated
2020/04/04 03:56 UTC
Data Sources
Company Financials +
Executive Summary
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with questionable track record.
Similar Companies
Share Price & News
How has Regeneron Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: REGN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
9.7%
REGN
2.5%
US Biotechs
-2.0%
US Market
1 Year Return
20.6%
REGN
-0.9%
US Biotechs
-15.1%
US Market
Return vs Industry: REGN exceeded the US Biotechs industry which returned -0.6% over the past year.
Return vs Market: REGN exceeded the US Market which returned -14.9% over the past year.
Shareholder returns
| REGN | Industry | Market | |
|---|---|---|---|
| 7 Day | 9.7% | 2.5% | -2.0% |
| 30 Day | 1.1% | -8.3% | -19.7% |
| 90 Day | 33.6% | -4.1% | -23.2% |
| 1 Year | 20.6%20.6% | -0.2%-0.9% | -13.4%-15.1% |
| 3 Year | 29.6%29.6% | 13.8%10.9% | 10.9%3.7% |
| 5 Year | 6.9%6.9% | -7.2%-11.6% | 28.4%14.4% |
Price Volatility Vs. Market
How volatile is Regeneron Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
A Look At The Intrinsic Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)1 month ago | Simply Wall St
Have Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insiders Been Selling Their Stock?1 month ago | Simply Wall St
A Rising Share Price Has Us Looking Closely At Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) P/E RatioValuation
Is Regeneron Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
25.46x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: REGN ($498.75) is trading above our estimate of fair value ($429.51)
Significantly Below Fair Value: REGN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: REGN is poor value based on its PE Ratio (25.7x) compared to the Biotechs industry average (15.7x).
PE vs Market: REGN is poor value based on its PE Ratio (25.7x) compared to the US market (12.5x).
Price to Earnings Growth Ratio
PEG Ratio: REGN is poor value based on its PEG Ratio (2.9x)
Price to Book Ratio
PB vs Industry: REGN is overvalued based on its PB Ratio (4.9x) compared to the US Biotechs industry average (2.6x).
Next Steps
Future Growth
How is Regeneron Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?
8.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: REGN's forecast earnings growth (8.8% per year) is above the savings rate (1.7%).
Earnings vs Market: REGN's earnings (8.8% per year) are forecast to grow slower than the US market (12.2% per year).
High Growth Earnings: REGN's earnings are forecast to grow, but not significantly.
Revenue vs Market: REGN's revenue (6.4% per year) is forecast to grow slower than the US market (7.1% per year).
High Growth Revenue: REGN's revenue (6.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: REGN's Return on Equity is forecast to be low in 3 years time (18.1%).
Next Steps
Past Performance
How has Regeneron Pharmaceuticals performed over the past 5 years?
34.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: REGN has high quality earnings.
Growing Profit Margin: REGN's current net profit margins (26.9%) are lower than last year (36.4%).
Past Earnings Growth Analysis
Earnings Trend: REGN's earnings have grown significantly by 34.4% per year over the past 5 years.
Accelerating Growth: REGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: REGN had negative earnings growth (-13.4%) over the past year, making it difficult to compare to the Biotechs industry average (22%).
Return on Equity
High ROE: REGN's Return on Equity (19.1%) is considered low.
Next Steps
Financial Health
How is Regeneron Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: REGN's short term assets ($7.7B) exceed its short term liabilities ($2.1B).
Long Term Liabilities: REGN's short term assets ($7.7B) exceed its long term liabilities ($1.6B).
Debt to Equity History and Analysis
Debt Level: REGN is debt free.
Reducing Debt: REGN has no debt compared to 5 years ago when its debt to equity ratio was 5.7%.
Debt Coverage: REGN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: REGN has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: REGN has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if REGN's debt is covered by short term assets.
Next Steps
Dividend
What is Regeneron Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate REGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate REGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if REGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if REGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of REGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Leonard Schleifer (66yo)
32.25s
Tenure
US$26,520,555
Compensation
Dr. Leonard S. Schleifer, M.D., Ph.D., founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988. Dr. Schleifer served as the Chairman of Regeneron P ...
CEO Compensation Analysis
Compensation vs Market: Leonard's total compensation ($USD26.52M) is above average for companies of similar size in the US market ($USD11.87M).
Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 32.25yrs | US$26.52m | 2.12% $1.1b | |
| Founding Scientist | 19.25yrs | US$25.38m | 1.06% $566.6m | |
| Executive VP of Finance & CFO | 6.5yrs | US$9.36m | 0.023% $12.4m | |
| Executive VP and GM of Industrial Operations & Product Supply | 12yrs | US$9.01m | 0.027% $14.7m | |
| Senior Vice President of Commercial | 2.17yrs | US$10.28m | 0.013% $6.9m | |
| Senior Vice President of Quality Assurance & Operations | 0.25yr | no data | no data | |
| Senior Vice President of Technical Operations | 0.25yr | no data | no data | |
| Vice President of Investor Relations | 0.83yr | no data | no data | |
| Executive VP | 8.58yrs | US$3.38m | 0.013% $7.2m | |
| Senior VP | 1.25yrs | no data | no data |
2.8yrs
Average Tenure
59yo
Average Age
Experienced Management: REGN's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 32.25yrs | US$26.52m | 2.12% $1.1b | |
| Founding Scientist | 19.25yrs | US$25.38m | 1.06% $566.6m | |
| Independent Director | 9.42yrs | US$1.23m | 0.00073% $392.0k | |
| Chairman of the Board | 25.25yrs | US$6.35m | 0.49% $264.6m | |
| Independent Director | 17.25yrs | US$1.23m | 0.027% $14.4m | |
| Independent Director | 28.83yrs | US$1.23m | 0.018% $9.9m | |
| Independent Director | 28.83yrs | US$1.22m | 0.0083% $4.4m | |
| Independent Director | 32.25yrs | US$1.23m | 0.12% $64.1m | |
| Independent Director | 8.42yrs | US$1.21m | 0.0011% $585.4k | |
| Independent Director | 3.58yrs | US$1.22m | no data |
22.3yrs
Average Tenure
68.5yo
Average Age
Experienced Board: REGN's board of directors are seasoned and experienced ( 22.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: REGN insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Regeneron Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Regeneron Pharmaceuticals, Inc.
- Ticker: REGN
- Exchange: NasdaqGS
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$53.702b
- Shares outstanding: 108.86m
- Website: https://www.regeneron.com
Number of Employees
Location
- Regeneron Pharmaceuticals, Inc.
- 777 Old Saw Mill River Road
- Tarrytown
- New York
- 10591
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| REGN | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Apr 1991 |
| RGO | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Apr 1991 |
| REGN | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Apr 1991 |
| 0R2M | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Apr 1991 |
| REGN * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Apr 1991 |
| REGN | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Apr 1991 |
| RGO | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Apr 1991 |
| REGN34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 1 REP 0.2 COM USD0.001 | BR | BRL | May 2019 |
Biography
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services for the development of new treatments combating the coronavirus. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/04 03:56 |
| End of Day Share Price | 2020/04/03 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.